OPHIDION, INC.
Non-invasive brain delivery technology platform for central nervous system therapeutics
- Sector
- Biotech
- Headquarters
- Bethlehem, PA
- Latest Form D
- $655K, Oct 2024
- Total capital
- $3.8M
- Federal grants
- $793K
- 2 awards · 2015–2016
- Rank in peer group#69 of 502
- Private capital raised
- $3M
- 3 Form D · last Oct 2024
- 25 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 6
- 12 pending · first 2016
- Rank in peer group#13 of 502
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$655K
- Private capital raisedForm D · SEC · 2nd filing$1.6M
- Private capital raisedForm D · SEC · 1st filing$755K
- Federal grantHealth and Human S · Phase II · Development of a5 nicotinic receptor agonists for smoking cessation$407K
- Federal grantHealth and Human S · Phase II · Development of a5 nicotinic receptor agonists for smoking cessation$386K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
54months
from OPHIDION, INC.’s first federal award to its first private round.
- First federal award · Apr 2015
- Health and Human S · $386K
- First Form D · Oct 2019
- $755K · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grants#69 · top 14%
- Granted patents#13 · top 3%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Claudine BruckDirectorNamed in SEC Form D filings
- Julie MiwaDirector, PromoterNamed in SEC Form D filings
- Michael LarkDirectorNamed in SEC Form D filings
- Scott FishmanDirectorNamed in SEC Form D filings
- Yacoub HabibExecutive Officer, PromoterNamed in SEC Form D filings
What it has protected
USPTO · 6 granted of 18- GrantedCompositions And Methods For Transport Across The Blood Brain BarrierUSPTOUS 12,208,143
- GrantedCompositions And Methods For Transport Across The Blood Brain BarrierUSPTOUS 11,376,331
- GrantedCompositions And Methods For Transport Across The Blood Brain BarrierUSPTOUS 10,772,966
Show all 18 patent records
- Compositions And Methods For Transport Across The Blood Brain BarrierJan 28, 2025 · US 12,208,143Granted
- Compositions And Methods For Transport Across The Blood Brain BarrierJul 5, 2022 · US 11,376,331Granted
- Compositions And Methods For Transport Across The Blood Brain BarrierSep 15, 2020 · US 10,772,966Granted
- Compositions And Methods For Treating LYNX2 DisordersFeb 27, 2020 · Application 16612364Pending
- Compositions And Methods For Transport Across The Blood Brain BarrierJun 25, 2019 · US 10,328,156Granted
- Compositions And Methods For Transport Across The Blood Brain BarrierMar 13, 2018 · US 9,913,915Granted
- Compositions And Methods For Transport Across The Blood Brain BarrierDec 20, 2016 · US 9,522,193Granted
- Compositions And Methods For Transport Across The Blood Brain BarrierApplication PCTUS2012040640Pending
- Compositions And Methods For Anti-sense Oligonucleotide (aso) Treatment Of Huntington's DiseaseApplication 19123719Pending
- Low Dose Sirna Treatments Of Huntington's DiseaseApplication 19581450Pending
- Delivery Of Molecules Across The Blood Brain BarrierApplication PCTUS2025029207Pending
- Compositions And Methods For Delivery Of Low Dose Effector AgentsApplication 19162000Pending
- Low Dose Sirna Treatments Of Huntington's DiseaseApplication PCTUS2024052499Pending
- Compositions And Methods For Delivery Of Low Dose Effector AgentsApplication PCTUS2024018232Pending
- LOW DOSE siRNA TREATMENTS OF HUNTINGTON'S DISEASEApplication 63592542Pending
- Compositions And Methods For Anti-sense Oligonucleotide (aso) Treatment Of Huntington's DiseaseApplication PCTUS2023017275Pending
- Compositions And Methods For Delivery Of Low Dose Effector AgentsApplication 63449826Pending
- Low Dose Anti-sense Oligonucleotide (aso) Treatments For Huntington's DiseaseApplication 63418945Pending
Related companies, and why
- DARE BIOSCIENCE, INC.Similar federal contract value in Biotech · null in contracts
- Karuna TherapeuticsSimilar federal contract value in Biotech · null in contracts
- TFF PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
- WESTERN ONCOLYTICS, LTDSimilar federal contract value in Biotech · null in contracts
- ELASTRIN THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Paulex Bio Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .